Vutrisiran: First Approval

Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis

(2022) Yukio Ando et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

RNA-targeting and gene editing therapies for transthyretin amyloidosis

(2022) Alberto Aimo et al.   Nature Reviews Cardiology

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges

(2022) Carsten Tschöpe et al.   Journal of Clinical Medicine

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

(2022) David Adams et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care

(2020) Marco Luigetti et al.   Therapeutics and Clinical Risk Management

STUDY DESIGN AND RATIONALE OF HELIOS-B: A PHASE 3 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY

(2020) Rebecca Shilling et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

(2020) Bahru A. Habtemariam et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

(2018) David Adams et al.   NEW ENGLAND JOURNAL OF MEDICINE